News | Breast Imaging | May 16, 2023

DenseBreast-info.org has issued a statement which states that the USPSTF Guideline should not apply to women with dense breasts, stating that the newly released United States Preventive Services Task Force (USPSTF) breast cancer screening recommendations are written for women at “average” risk for breast cancer

DenseBreast-info.org has issued a statement which states that the USPSTF Guideline should not apply to women with dense breasts, stating that the newly released United States Preventive Services Task Force (USPSTF) breast cancer screening recommendations are written for women at “average” risk for breast cancer

Getty Images


May 16, 2023 — DenseBreast-info.org has issued a statement which states that the USPSTF Guideline should not apply to women with dense breasts, stating that the newly released United States Preventive Services Task Force (USPSTF) breast cancer screening recommendations are written for women at “average” risk for breast cancer. But women with dense breasts are at higher risk. Further, the task force incorrectly concludes there is “inadequate” evidence to support adding screening MRI (or ultrasound if MRI is not possible) after a mammogram for many women with dense breasts.

Dense Breasts and Higher Risk

The task force guideline only addresses women at average risk yet includes women with dense breasts or with a family history of breast cancer in that group. The task force did not consider combinations of risk factors. Many women with dense breasts also have a family history of breast cancer and meet current “high-risk” criteria (greater than 20% lifetime risk). In these women, annual screening with MRI is recommended, in addition to annual mammography, by the American Cancer Society (ACS), National Comprehensive Cancer Network (NCCN) guidelines, American College of Radiology (ACR) Appropriateness Criteria, and the 2023 ACR Screening Recommendations for Women at Higher than Average Risk. MRI, or ultrasound if MRI is not possible, should be recommended in women where annual mammography alone is inadequate, and this includes all women at higher risk.

FDA Final Rule

A new FDA rule going into effect in September 2024 will require all women be told that dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. In women with the densest breasts, about 40% of cancers are missed on a mammogram. About 40% of women of mammography age have dense breasts.

FDA, Additional Testing and Insurance Coverage

With the FDA final rule, women with dense breasts will also be informed, “in some people with dense tissue, other imaging tests in addition to mammography may help find cancers.” Women with dense breasts will be told other imaging tests are helpful, but, because the USPSTF does not recognize the benefit of this additional testing, their insurance may not cover such testing.

Why it Matters

Insurance, medicare, and the affordable care act rely on USPSTF recommendations to determine coverage of screening tests. Additional testing may not be covered by insurance if not recommended by the USPSTF. Women who need additional breast imaging tests may not be able to afford them due to lack of insurance coverage.

Need for the Find It Early Act

Many women with dense breasts are at higher risk for breast cancer and for missed cancer on a mammogram. Therefore, the USPSTF recommendations should not be applied to these women. The current USPSTF recommendations may cause confusion and prevent women who need additional screening from being able to access and afford it. The proposed bipartisan insurance coverage bill, the Find It Early Act (introduced by Reps. DeLauro and Fitzpatrick), may help. Insurance coverage should be consistent with NCCN Guidelines and ACR Appropriateness Criteria, and the Find It Early Act would ensure this for all women.

DenseBreast-info.org urges people to support the Find it Early Act, and offers details for contacting your congressperson here

For more information: www.densebreast-info.org

Related USPSTF Guideline Content:

Task Force Issues New Draft Recommendation Statement on Screening for Breast Cancer

RSNA Updates Its Position Statement on Screening for Breast Cancer

ACR/SBI Statement on New USPSTF Breast Cancer Screening Recommendations

Hologic Statement on Recently Released USPSTF Breast Cancer Screening Guidelines

Related Breast Density Content:

VIDEO: Research and Advancements in Breast Imaging Technology

VIDEO: FDA Update on the US National Density Reporting Standard - A Discussion on the Final Rule

One on One … with Wendie Berg, MD, PhD, FACR, FSBI

Creating Patient Equity: A Breast Density Legislative Update

FDA Needs to Ensure that Information on Dense Breast Notifications are Clear and Understandable to all Members of the Public

AI Provides Accurate Breast Density Classification

VIDEO: The Impact of Breast Density Technology and Legislation

VIDEO: Personalized Breast Screening and Breast Density

VIDEO: Breast Cancer Awareness - Highlights of the NCoBC 2016 Conference

Fake News: Having Dense Breast Tissue is No Big Deal

The Manic World of Social Media and Breast Cancer: Gratitude and Grief

Related Breast Imaging Content:

Single vs. Multiple Architectural Distortion on Digital Breast Tomosynthesis

Today's Mammography Advancements 

Digital Breast Tomosynthesis Spot Compression Clarifies Ambiguous Findings 

AI DBT Impact on Mammography Post-breast Therapy 

ImageCare Centers Unveils PINK Better Mammo Service Featuring Profound AI 

Radiologist Fatigue, Experience Affect Breast Imaging Call Backs 

Fewer Breast Cancer Cases Between Screening Rounds with 3-D Mammography

Study Finds Racial Disparities in Access to New Mammography Technology

American College of Radiology (ACR) Launches Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) in Collaboration With GE Healthcare and the Breast Cancer Research Foundation


Related Content

News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time April 15, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
News | Mammography

April 11, 2024 — Volpara Health Technologies Ltd., a global leader in software for the early detection and prevention of ...

Time April 11, 2024
arrow
News | Society of Breast Imaging (SBI)

April 11, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced today ...

Time April 11, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

In a new 3-part video series on advancements in diagnostic radiology with Robert L. Bard, MD, PC, DABR, FASLMS ...

Time April 10, 2024
arrow
Subscribe Now